News
31 March 2020

EIB finances AM-Pharma's development of acute kidney injury treatment

In:
Infrastructure
Region:
Europe

The EIB and Utrecht-based AM-Pharma have signed a €24 million financing agreement. The funds will be used to accelerate the development of the clinical stage biopharmaceutical company’s recombinant alkaline phosphatase enzyme, which is used to treat acute kidney injury (AKI). The...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Perspective
02 March 2026

Cocobod announces plans for reform as cocoa prices crater

Cocoa prices have returned to historical averages but the threat of volatility remains, and national regulators are still managing the fallout. Ghana’s Cocobod has committed...

Perspective
03 March 2026

Sonangol financing: A benchmark in SACE support

The SACE-backed loan to fund Sonangol’s equity share in the NeGaCo gas project in Angola has marked the first time the ECA has structured such a deal based on the total...